Surrozen, Inc. Form 8-K Summary
Report date: March 22, 2023; filed March 23, 2023. The filing provides a business update and estimated unaudited preliminary financial results for the fourth quarter and year ended December 31, 2022.
Business Context and Pipeline
Surrozen is a biotechnology company developing Wnt pathway therapeutics. Its lead programs include SZN-043 for severe liver disease, initially severe alcoholic hepatitis, and SZN-1326 for moderate to severe ulcerative colitis. The company also has discovery programs focused on the lacrimal gland and cornea.
- SZN-043: Completed enrollment of the second healthy-volunteer Phase 1a cohort; enrolled the first patient with chronic liver disease. Data are expected by year-end 2023.
- SZN-043: Phase 1b in severe alcoholic hepatitis is planned for 2024, with potential proof-of-concept data in the second half of 2024.
- SZN-1326: Phase 1a in healthy volunteers is expected to restart by mid-2023 at a lower dose based on the Minimum Anticipated Biological Effect Level. Phase 1a data are expected by year-end 2023.
- SZN-1326: Potential ulcerative-colitis proof-of-concept data are anticipated in the second half of 2024.
- Discovery pipeline: The company expects to nominate a fourth development candidate by the end of 2023 and/or potentially enter into a strategic partnership.
Financial Results and Liquidity
| Metric | Q4 2022 | Full Year 2022 | Comparable 2021 |
|---|---|---|---|
| Collaboration and license revenue | $12.5 million | $12.5 million | $0 |
| Research and development expense | $9.4 million | $37.0 million | $10.9 million / $40.2 million |
| General and administrative expense | $5.2 million | $19.8 million | $4.1 million / $14.2 million |
| Interest income | $0.5 million | $0.8 million | $42,000 / $0.1 million |
| Other income, net | $0.9 million | $7.6 million | ($1,000) / ($0.3 million) |
| Net loss | $0.8 million | $36.0 million | $15.0 million / $54.6 million |
Cash, cash equivalents and marketable securities totaled $75.8 million at December 31, 2022, compared with $123.5 million at December 31, 2021. The filing does not provide a clear debt balance, operating cash-flow figure, or profit margin. The reported results are preliminary, unaudited, and subject to closing adjustments.
Material Changes Versus Prior Period
- Collaboration and license revenue increased from zero to $12.5 million in 2022, primarily from the non-refundable upfront payment under the October 2022 collaboration and license agreement.
- Full-year research and development expense declined by $3.2 million, primarily because manufacturing drug substance for SZN-1326 and SZN-043 was completed in 2021.
- Full-year general and administrative expense increased by $5.6 million due primarily to employee-related costs, stock-based compensation, insurance, professional services, and public-company costs.
- Full-year net loss decreased by $18.6 million, primarily reflecting collaboration revenue, lower research and development expense, and higher other income.
- Interest income increased with higher interest rates on money market funds and marketable securities.
Outlook, Partnerships, and Risks
Following prioritization and restructuring activities, management stated that the company expects its cash runway to extend into the second half of 2024 and will prioritize investments in key clinical and discovery programs. However, the forward-looking-statement section refers to an expected runway into the second half of 2023. This inconsistency should be verified against the final filing and subsequent disclosures.
Under its fourth-quarter 2022 partnership with Boehringer Ingelheim, Surrozen is developing SZN-413 for retinal diseases. Identification of a lead Fzd-4-targeted Wnt agonist candidate by the end of 2023 could trigger a $10 million milestone payment.
Surrozen reported that it has filed or licensed more than 20 patent families related to Wnt pathway discoveries and modulation. The USPTO recently issued notices of allowance for two Surrozen-assigned patent families related to SZN-1326.
Key risks include the timing, cost, and results of preclinical and clinical trials; the ability to fund development activities or raise additional capital; regulatory and commercialization risks; global economic and market volatility; and the possibility that actual results differ materially from management’s plans. The financial results have not been audited.
Facts Investors Should Verify
- Final audited 2022 results and any changes from the preliminary figures.
- The cash runway statement, particularly the discrepancy between “second half of 2024” and “second half of 2023.”
- Current cash, marketable securities, operating cash burn, debt, and future financing requirements.
- Progress and data timing for the SZN-043 and SZN-1326 clinical programs.
- Terms and achievement status of the Boehringer Ingelheim collaboration and the potential $10 million milestone.
- Whether the planned fourth development candidate or a strategic partnership is achieved by year-end 2023.